Presentations and Publications
Read about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to NASDAQ, read details in our Investor Centre.2021
2017
Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular Dystrophy.
Joint 10th AGCST and ASSCR Scientific Meeting, Sydney
25 MAY 2017
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Nat. Commun. 8, 14848 doi: 10.1038/ ncomms14848 (2017)
1 JAN 20172016
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liver
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
Gene Therapy Rescues Disease Phenotype in the Oculopharyngeal Muscular Dystrophy Mouse Model
ASGCT 19th Annual Meeting, Washington DC
5 MAY 20162015
Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)
The Liver Meeting (AASLD), San Francisco
14 NOV 2015
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
The Liver Meeting (AASLD), San Francisco
13 NOV 2015